Takeda Pharmaceutical Co. Ltd. signed an agreement with a privately held biotechnology company to discover and develop therapeutics for liver diseases.
While financial terms of the deal were not disclosed, HemoShear Therapeutics LLC will receive an upfront payment, research and development funding, up to $470 million in milestone-related payments, and royalties on the sales of any commercialized drug.
Takeda will receive exclusive access to HemoShear's proprietary disease modeling platform, REVEAL-Tx, to discover and develop therapeutics for specific liver diseases, including nonalcoholic steatohepatitis, or NASH, and liver fibrosis.
The U.S. Food and Drug Administration has yet to approve a treatment for NASH and liver fibrosis.
REVEAL-Tx replicates human diseases with great accuracy in clinical conditions to allow drug candidates to be studied at human concentrations.